SCHEMBL15440670

SCHEMBL15440670

CCN(CC)CCc1cc2c3c(nn(CCN(C)C)c(=O)c3c1)-c1ccccc1C2=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.60
▸ HTT P42858 2/20 0.60
▸ L3MBTL1 Q9Y468 2/20 0.60
▸ NPC1 O15118 1/20 0.60
▸ MITF O75030 1/20 0.60
▸ DNMT1 P26358 1/20 0.60
▸ RAD52 P43351 1/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ UHRF1 Q96T88 1/20 0.60
▸ ADRA1A P35348 2/20 0.39
▸ HRH1 P35367 2/20 0.39
▸ ADRA1B P35368 2/20 0.39
▸ MAPK13 O15264 1/20 0.35
▸ EIF2AK2 P19525 1/20 0.35
▸ MAPK12 P53778 1/20 0.35
▸ MAPK11 Q15759 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13281541 0.81 HTT (0.52) POLBHTTL3MBTL1NPC1MITF
SCHEMBL15440804 0.80 HTT (0.67) POLBHTTL3MBTL1NPC1MITF
SCHEMBL13282030 0.76 NPC1 (0.46) POLBHTTL3MBTL1NPC1MITF
SCHEMBL12349852 0.75 POLB (1.00) POLBHTTL3MBTL1NPC1MITF
SCHEMBL30567461 0.75 POLB (1.00) POLBHTTL3MBTL1NPC1MITF
SCHEMBL15440705 0.74 POLB (0.57) POLBHTTL3MBTL1NPC1MITF
SCHEMBL15440660 0.74 RAB9A (0.43) POLBHTTL3MBTL1NPC1MITF
SCHEMBL13281764 0.71 NPC1 (0.52) POLBHTTL3MBTL1NPC1MITF
SCHEMBL15440787 0.71 HTT (0.52) POLBHTTL3MBTL1NPC1MITF
SCHEMBL15440739 0.69 RAB9A (0.50) POLBHTTL3MBTL1NPC1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096536-B2 Asymmetrically substituted anthrapyridazone derivatives as cytostatics BS-154 S.P. ZO.O. (PL) 2015-08-04 — — US claimed
US-20140031357-A1 ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS BS-154 SP. Z O.O. (PL) 2014-01-30 — — US claimed
US-9096536-B2 Asymmetrically substituted anthrapyridazone derivatives as cytostatics BS-154 S.P. ZO.O. (PL) 2015-08-04 — — US disclosed
US-20140031357-A1 ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS BS-154 SP. Z O.O. (PL) 2014-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031357-A1 ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS ABCC1, ABCC3, ABCB1 POLB 1452/4885HTT 3062/4885L3MBTL1 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback